Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech continues to gather up trial data for a potential FDA approval next year.  | Telehealth ...

Particle therapy using a mix of carbon-, oxygen- and neon-ion beams helps tune the fine balance between range robustness, uniform dose and high linear energy transfer ...

Hims & Hers Health shares are trending Wednesday after the company announced it launched access to the Hims & Hers Multi-Cancer Test.

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

Last week, the U.S. Food and Drug Administration (FDA) approved the use of Darzalex Faspro (daratumumab and ...

NHS patients will be told their real-time cancer risk with the help of gadgets such as smartwatches. Everyone will be able to access “real-time personalised insights about their cancer risk” within a ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Investing.com -- Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 6% on Wednesday after the digital health platform announced it is launching access to a multi-cancer early detection test that can ...

The company unveiled a blood test to detect signals for more than 50 types of cancer.